Expression of EGF, HB-EGF, TGF-oc, HRG-oc, HRG-f1, and HRG-P3 in 100 frozen breast carcinoma materials was immunohistochemically studied. Among these tumors, 67% were positive for EGF, 53% for HB-EGF, 57% for TGF-a, 60% for HRGax, 53% for HRG-31, and 63% for HRG-f3 in the neoplastic epithelial cells. No significant associations between expression of the growth factors and clinicopathological features like tumor size, histologic grade, node status, ploidy, ER status, and c-erbB-4 expression were observed, with the exceptions that significant relations were present between EGF expression and tumor size (p = 0.01) and between HRG-P3 expression and node status (p =0.02). The expressions of these growth factors showed no associationwith cancer-specific survival by the Kaplan Meier analysis.
1. Cohen BD, Siegall CB, Bacus S, Foy L, Green JM, Hellstrom I, Hellstrom KE, Fell HP. Role of epidermal growth factor receptor family members in growth and differentiation of breast carcinoma. Biochem Soc Symp63:199-210, 1998
2.
2. Gullick WJ, Srinivasan R. The type 1 growth factor receptor family: New ligands and receptors and their role in breast cancer. Breast Cancer Res Treat52:43-53, 1998
3.
3. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res77:25-79, 2000
4.
4. Grunt TW, Saceda M, Martin MB, Lupu R, Dittrich E, Krupitza G, Harant H, Huber H, Dittrich C. Bidirectional interactions between the estrogen receptor and the c-erbB-2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer63:560-567, 1995
5.
5. Kew TY, Bell JA, Pinder SE, Denley H, Srinivasan R, Gullick WJ, Nicholson RI, Blamey RW, Ellis 10. cerbB-4 protein expression in human breast cancer. Br J Cancer82:1163-1170, 2000
6.
6. Offterdinger M, Schneider SM, Huber H, Grunt TW. Expression of c-erbB-4/HER4 is regulated in T47D breast carcinoma cells by retinoids and vitamin D3. Biochem Biophys Res Commun258:559-564, 1999
7.
7. Ram TG, Ethier SP. Phosphatidylinositol 3-kinase recruitment by pl85erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. Cell Growth Differ7:551-561, 1996
8.
8. Suo Z, Emilsen E, Tveit KM, Nesland JM. Type 1 protein tyrosine kinases in benign and malignant breast lesions. Histopathology33:514-521, 1998
9.
9. Burden S, Yarden Y. Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis. Neuron18:847-855, 1997
10.
10. Olayioye MA, Neve RM, Lane HA, Hynes NE. New EMBO Members' Review. The ErbB signaling network: Receptor heterodimerization in development and cancer. Embo J19:3159-3167, 2000
11.
11. Whoriskey JS, Pekar SK, Elliott GS, Hara S, Liu N, Lenz DM, Zamborelli T, Mayer JP, Tarpley JE, Lacey DL, Ratzkin B, Yoshinaga SK. A neu differentiation factor (NDF) domain essential for proliferation and alterations in morphology of colonic epithelial cells in vitro. Growth Factors15:307-321, 1998
12.
12. Wen D, Peles E, Cupples R, Suggs SV, Bacus SS, Luo Y, Trail G, Hu S, Silbiger SM, Levy RB, et al. Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell69:559-572, 1992
13.
13. Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Levy RB, Yarden Y. Isolation of the neu/HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell69:205-216, 1992
14.
14. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD, et al. Identification of heregulin, a specific activator of pl85erbB2. Science256:1205-1210, 1992
15.
15. Carraway KL III, Cantley LC. A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling. Cell78:5-8, 1994
16.
16. Wen D, Suggs SV, Karunagaran D, Liu N, Cupples RL, Luo Y, Janssen AM, Ben-Baruch N, Trollinger DB, Jacobsen VL, et al. Structural and functional aspects of the multiplicity of neu differentiation factors. Mol Cell Biol14:1909-1919, 1994
17.
17. World Health Organization. In: International Histological Classification of Tumors. No. 2. Histological Typing of Breast Tumors. World Health Organization, Geneva, 1981
18.
18. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology19:403-410, 1991
19.
19. Vindelov LL, Christensen IJ, Nissen NI. A detergenttrypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry3:323-327, 1983
20.
20. Risberg B, Stal O, Eriksson LL, Hussein A. DNA flow cytometry on breast carcinomas: Comparison of a detergent and an enzyme-detergent preparation method. Anal Cell Pathol2:287-295, 1990
21.
21. Baisch H, Beck HP, Christensen IJ, Hartmann NR, Fried J, Dean PN, Gray JW, Jett JH, Johnston DA, White RA, Nicolini C, Zeitz S, Watson JV. A comparison of mathematical methods for the analysis of DNA histograms obtained by flow cytometry. Cell Tissue Kinet15:235-249, 1982
22.
22. Pinto AE, Andre S, Soares J. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: A multivariate analysis of prognostic markers in a series of 308 patients. J Clin Pathol52:604-611, 1999
23.
23. Suo Z, Berner HS, Risberg B, Karlsson MG, Nesland JM. ER-cx and c-erbB-4 expression in breast carcinomas. Virchows Archiv, in press
24.
24. Gregory H. In vivo aspects of urogastrone-epidermal growth factor. J Cell Sci (Suppl) 3:11-17, 1985
25.
25. Carpenter G, Zendegui JG. Epidermal growth factor, its receptor, and related proteins. Exp Cell Res164:1-10, 1986
26.
26. Crew AJ, Langdon SP, Miller EP, Miller WR. Mitogenic effects of epidermal growth factor and transforming growth factor-alpha on EGF-receptor positive human ovarian carcinoma cell lines. Eur J Cancer28:337-341, 1992
27.
27. Dong XF, Berthois Y, Martin PM. Effect of epidermal growth factor on the proliferation of human epithelial cancer cell lines: Correlation with the level of occupied EGF receptor. Anticancer Res11:737-743, 1991
28.
28. Mount CD, Lukas TJ, Orth DN. Characterization of a high-molecular-weight form of epidermal growth factor in an extract of human urine. Arch Biochem Biophys255:1-7, 1987
29.
29. Boccardo F, Torrisi R, Zanardi S, Valenti G, Pensa F, De Franchis V, Barreca A, Ferraro P, Minuto F. EGF in breast cyst fluid: Relationships with intracystic androgens, estradiol and progesterone. Int J Cancer47:523-526, 1991
30.
30. Kasselberg AG, Orth DN, Gray ME, Stahlman MT. Immunocytochemical localization of human epidermal growth factor/urogastrone in several human tissues. J Histochem Cytochem33:315-322, 1985
31.
31. Artagaveytia N, Le Penven S, Falette N, Lucero R, Garofalo EG, Saez S. Epidermal growth factor and transforming growth factor alpha mRNA expression in human breast cancer biopsies: Analysis in relation to estradiol, progesterone and EGF receptor content. J Steroid Biochem Mol Biol60:221-228, 1997
32.
32. Umekita Y, Enokizono N, Sagara Y, Kuriwaki K, Takasaki T, Yoshida A, Yoshida H. Immunohistochemical studies on oncogene products (EGF-R, cerbB-2) and growth factors (EGF, TGF-alpha) in human breast cancer: Their relationship to oestrogen receptor status, histological grade, mitotic index and nodal status. Virchows Arch A Pathol Anat Histopathol420:345-351, 1992
33.
33. Mizukami Y, Nonomura A, Noguchi M, Taniya T, Koyasaki N, Saito Y, Hashimoto T, Matsubara F, Yanaihara N. Immunohistochemical study of oncogene product ras p2 1, c-myc and growth factor EGF in breast carcinomas. Anticancer Res11:1485-1494, 1991
34.
34. Pirinen R, Lipponen P, Aaltomaa S, Syrjanen K. Prognostic value of epidermal growth factor expression in breast cancer. J Cancer Res Clin Oncol123:63-68, 1997
35.
35. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science251:936-939, 1991
36.
36. Higashiyama S, Lau K, Besner GE, Abraham JA, Klagsbrun M. Structure of heparin-binding EGFlike growth factor. Multiple forrns, primary structure, and glycosylation of the mature protein. J Biol Chem267:6205-6212, 1992
37.
37. Raab G, Higashiyama S, Hetelekidis S, Abraham JA, Damm D, Ono M, Klagsbrun M. Biosynthesis and processing by phorbol ester of the cells surface-associated precursor form of heparin-binding EGFlike growth factor. Biochem Biophys Res Commun204:592-597,1994
38.
38. Aviezer D, Yayon A. Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Proc Natl Acad Sci USA91:12173-12177, 1994
39.
39. Higashiyama S, Iwamoto R, Goishi K, Raab G, Taniguchi N, Klagsbrun M, Mekada E. The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol128:929-938, 1995
40.
40. Elenius K, Paul S, Allison G, Sun J, Klagsbrun M. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. Embo J16:1268-1278, 1997
41.
41. Sartor CI, Dziubinski ML, Yu CL, Jove R, Ethier SP. Role of epidermal growth factor receptor and STAT3 activation in autonomous proliferation of SUM102PT human breast cancer cells. Cancer Res57:978-987, 1997
42.
42. Ciardiello F, Kim N, McGeady ML, Liscia DS, Saeki T, Bianco C, Salomon DS. Expression of transforming growth factor alpha (TGF alpha) in breast cancer. Ann Oncol2:169-182, 1991
43.
43. Derynck R. Transforming growth factor alpha. Cell54:593-595, 1988
44.
44. Normanno N, Ciardiello F, Brandt R, Salomon DS. Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. Breast Cancer Res Treat29:11-27, 1994
45.
45. Parham DM, Jankowski J. Transforming growth factor alpha in epithelial proliferative diseases of the breast. J Clin Pathol45:513-516, 1992
46.
46. Mizukami Y, Nonomura A, Yamada T, Kurumaya H, Hayashi M, Koyasaki N, Taniya T, Noguchi M, Nakamura S, Matsubara F. Immunohistochemical demonstration of growth factors, TGF-alpha, TGFbeta, IGF-I and neu oncogene product in benign and malignant human breast tissues. Anticancer Res10:1115-1126, 1990
47.
47. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol184:44-52, 1998
48.
48. Lundy J, Schuss A, Stanick D, McCormack ES, Kramer S, Sorvillo JM. Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer. Correlation with clinicopathologic parameters. Am J Pathol138:1527-1534, 1991
49.
49. Qi CF, Liscia DS, Normanno N, Merlo G, Johnson GR, Gullick WJ, Ciardiello F, Saeki T, Brandt R, Kim N, et al. Expression of transforming growth factor alpha, amphiregulin and cripto-I in human breast carcinomas. Br J Cancer69:903-910, 1994
50.
50. Soares R, Pereira MB, Silva C, Amendoeira I, Wagner R, Ferro J, FC S. Expression of TGF-oc and EGFR in breast cancer and its relation to angiogenesis. Breast J6:171-177, 2000
51.
51. Barrett-Lee P, Travers M, Luqmani Y, Coombes RC. Transcripts for transforming growth factors in human breast cancer: Clinical correlates. Br J Cancer61:612-617, 1990
52.
52. Travers MT, Barrett-Lee PJ, Berger U, Luqmani YA, Gazet JC, Powles TJ, Coombes RC. Growth factor expression in normal, benign, and malignant breast tissue. Br Med J (Clin Res Ed)296:1621-1624, 1988
53.
53. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-I via phosphatidylinositol-3 kinase. J Biol Chem273:28238-28246, 1998
54.
54. Schelfhout VR, Coene ED, Delaey B, Thys S, Page DL, De Potter CR. Pathogenesis of Paget's disease: Epidermal heregulin-alpha, motility factor, and the HER receptor family. J Natl Cancer Inst92:622-628, 2000
55.
55. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D, Tang C. The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat38:57-66, 1996
56.
56. Lewis GD, Lofgren JA, McMurtrey AE, Nuijens A, Fendly BM, Bauer KD, Sliwkowski MX. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB-2 as a critical component in mediating heregulin responsiveness. Cancer Res56:1457-1465, 1996
57.
57. Guerra-Vladusic FK, Scott G, Weaver V, Vladusic EA, Tsai MS, Benz CC, Lupu R. Constitutive expression of heregulin induces apoptosis in an erbB-2 overexpressing breast cancer cell line SKBr-3. Int J Oncol15:883-892, 1999
58.
58. Yoo JY, Lessor T, Hamburger AW. Inhibition of cell proliferation by 17 beta-estradiol and heregulin betal in estrogen receptor negative human breast carcinoma cell lines. Breast Cancer Res Treat51:71-81, 1998
59.
59. Weinstein EJ, Grimm S, Leder P. The oncogene heregulin induces apoptosis in breast epithelial cells and tumors. Oncogene17:2107-2113, 1998
60.
60. Normanno N, Kim N, Wen D, Smith K, Harris AL, Plowman G, Colletta G, Ciardiello F, Salomon DS. Expression of messenger RNA for amphiregulin, heregulin, and cripto1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res Treat35:293-297, 1995
61.
61. Bacus SS, Gudkov AV, Zelnick CR, Chin D, Stern R, Stancovski I, Peles E, Ben-Baruch N, Farbstein H, Lupu R, et al. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: Implications for mammary tumors. Cancer Res53:5251-5261, 1993
62.
62. Visscher DW, Sarkar FH, Kasunic TC, Reddy KB. Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia. Breast Cancer Res Treat45:75-80, 1997
63.
63. Chang H, Riese DJ II, Gilbert W, Stern DF, McMahan UJ. Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature387:509-512, 1997
64.
64. Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC, Yarden Y. Neuregulin-4: A novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene18:2681-2689, 1999
65.
65. Adlkofer K, Lai C. Role of neuregulins in glial cell development. Glia29:104-111, 2000
66.
66. Narita T, Kawakami-Kimura N, Sato M, Matsuura N, Higashiyama S, Taniguchi N, Kannagi R. Alteration of integrins by heparin-binding EGF-like growth factor in human breast cancer cells. Oncology53:374-381, 1996
67.
67. Hofmann GE, Scott RT Jr, Bergh PA, Deligdisch L. Immunohistochemical localization of epidermal growth factor in human endometrium, decidua, and placenta. J Clin Endocrinol Metab73:882-887, 1991
68.
68. Sakakibara H, Taga M, Saji M, Kida H, Minaguchi H. Gene expression of epidermal growth factor in human endometrium during decidualization. J Clin Endocrinol Metab79:223-226, 1994
